Isakova et al. [160] suggested that dietary phosphate restriction in combination with phosphate binder therapy may play a role in reducing FGF-23 levels in patients with CKD stages 3–4 and normal serum phosphate levels, since FGF-23 is recognized as a novel risk factor for ESRD, cardiovascular disease, and mortality. This evidence concerns the gene FGF23 and chronic kidney disease.